Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of GC3111B Tdap Vaccine in Healthy Adults
NCT06997627Phase 2Recruiting
- Sponsor
- GC Biopharma Corp
- Start
- Jun 2025
- Primary completion
- May 2026
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of GC3111B in Tetanus, diphtheria and pertussis (2 arms), sponsored by GC Biopharma Corp. Primary endpoints: Solicited adverse events at 14 days, Unsolicited adverse events at 28 days and 3 more. Started Jun 2025; status: recruiting.
02
Drugs
GC3111B
03
Conditions
Tetanusdiphtheriapertussis
Beyond the preview
Go deeper on NCT06997627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06997627.